🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Clinical Trials in Egypt / NCT07277673
Recruiting Not applicable

Aerobic Exercise Addition to Cognitive Behavioural Treatment in Impotence Metabolic-syndrome Drinkers

NCT07277673 · tracked via the Priya Life Science Egypt tracker
Phase
Not applicable
Started
2025-10-10
Last updated
2025-12-11

Condition(s) studied

Heavy DrinkingMetabolic SyndromeImpotence

Investigational drug(s) / intervention(s)

aerobci physical training and cognitive behavioural treatmentCognitive behavioural treatment

aerobci physical training and cognitive behavioural treatment: Twenty men with Heavy Drinking, Impotence, and Metabolic Syndrome receive Cognitive Behavioural Treatment (30 minute per the session , three times/week, for 12 weeks). Also, men will also adminsiter supervised aerobic training (walking on electrical treamill, 50 minute per the session, three times/week, for 12 weeks).

Cognitive behavioural treatment: Twenty men with Heavy Drinking, Impotence, and Metabolic Syndrome will receive Cognitive Behavioural Treatment (30 minute per the session , three times/week, for 12 weeks)

Study summary

Cognitive Behavioural Treatment is used as treatment for Heavy Drinking, Impotence, and Metabolic Syndrome. The efficacy of adding aerobic training to this treatment is not tested till now.

Eligibility

Sex
MALE
Min age
35 Years
Max age
45 Years
Healthy volunteers
No
Inclusion Criteria: * heavy drinking men (forty) * men who complain metabolic syndrome * men who complain impotence Exclusion Criteria: * cardiac problems * renal or hepatic or respiratory or neurogenic diseases,

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Cairo University Giza Dokki Recruiting

More Cairo University trials in Egypt

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07277673 on ClinicalTrials.gov ↗ ← All trials in Egypt